Personalized antibody therapy for advanced cancer
Part of Cancer clinical trials.
This study tests a new type of immunotherapy for people with advanced cancer that has not responded to standard treatments. It aims to see if this personalized approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have stage IV cancer that is refractory or progressive after at least one line of standard treatment
- You must have measurable disease and available tumor tissue for genomic testing
- You must have adequate organ function as determined by blood tests
- You must not have symptomatic brain metastases
- You must not have chronic active autoimmune disease
- You must not have had an organ transplant
- You must not have another cancer requiring treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an antibody treatment for people with stage IV cancer that has not responded to previous treatment. It aims to find a new option for patients with several types of advanced solid tumors.
This trial tests whether using a personalized approach (matching your tumor's genetic profile to a targeted drug) can help people with advanced solid cancers live longer. It is for people whose cancer is not responding to standard treatments and who have a genetic change that can be targeted by an FDA-approved drug not usually used for their cancer type.
This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
Hear when a new Soft Tissue Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.